This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Hispanic ethnicity is a risk factor for impaired glucose tolerance or latent type 2 diabetes. Among people with diabetes, Hispanic Americans are 4.5 to 6.6 times more likely to suffer from end-stage kidney disease, suggesting a rise in the prevalence of nephropathy in this population. An understanding of the relationship between genetic make-up (genotype) and drug pharmacokinetics in Hispanic Americans with diabetes is needed. This is important since knowledge of the role of ethnicity on drug therapy outcomes is required to make appropriate drug therapy decisions in this patient population. The objective of this 2-year study is to obtain genotype and phenotype information relating to cytochrome P-450 (CYP) drug metabolism in a group of Hispanic Americans with diabetes. The rationale for the study is that a linkage may exist between genotype, glycemic control, and drug therapy outcomes in this ethnic group.
The specific aims of this project are to 1) characterize kidney function in Hispanic Americans and 2) determine the drug metabolism gentoypes (CYP3A and CYP2C9) in Hispanic Americans. Study subjects will be recruited from a local Hispanic Health Center, with metabolic and pharmacokinetic studies to be conducted in our General Clinical Research Center. We expect that completion of this study will provide critical new information to the field of ethnic disparities research and pharmacogenomics, and improve cultural awareness of diabetes care among healthcare providers.
Showing the most recent 10 out of 411 publications
